Rigel Pharmaceuticals RIGL Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions.
The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's available-for-sale debt securities - unrealized loss position (>=12 months)?
- Rigel Pharmaceuticals (RIGL) reported available-for-sale debt securities - unrealized loss position (>=12 months) of 9 in Q4 2025.
- What does available-for-sale debt securities - unrealized loss position (>=12 months) mean?
- This identifies debt securities that have remained in an unrealized loss position for a year or more. It is a critical indicator of potential credit deterioration or long-term interest rate risk within the investment portfolio. Investors use this to assess the quality and duration of the company's debt holdings.